1. Home
  2. AACG vs EQ Comparison

AACG vs EQ Comparison

Compare AACG & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AACG
  • EQ
  • Stock Information
  • Founded
  • AACG 1999
  • EQ 2017
  • Country
  • AACG China
  • EQ United States
  • Employees
  • AACG N/A
  • EQ N/A
  • Industry
  • AACG Other Consumer Services
  • EQ Biotechnology: Pharmaceutical Preparations
  • Sector
  • AACG Real Estate
  • EQ Health Care
  • Exchange
  • AACG Nasdaq
  • EQ Nasdaq
  • Market Cap
  • AACG 51.9M
  • EQ 57.8M
  • IPO Year
  • AACG N/A
  • EQ 2018
  • Fundamental
  • Price
  • AACG $1.09
  • EQ $0.90
  • Analyst Decision
  • AACG
  • EQ Hold
  • Analyst Count
  • AACG 0
  • EQ 1
  • Target Price
  • AACG N/A
  • EQ $1.00
  • AVG Volume (30 Days)
  • AACG 23.8K
  • EQ 466.3K
  • Earning Date
  • AACG 11-12-2025
  • EQ 11-13-2025
  • Dividend Yield
  • AACG N/A
  • EQ N/A
  • EPS Growth
  • AACG N/A
  • EQ N/A
  • EPS
  • AACG N/A
  • EQ N/A
  • Revenue
  • AACG $39,316,403.00
  • EQ $4,392,000.00
  • Revenue This Year
  • AACG N/A
  • EQ N/A
  • Revenue Next Year
  • AACG N/A
  • EQ N/A
  • P/E Ratio
  • AACG N/A
  • EQ N/A
  • Revenue Growth
  • AACG 11.62
  • EQ N/A
  • 52 Week Low
  • AACG $0.70
  • EQ $0.27
  • 52 Week High
  • AACG $2.58
  • EQ $2.35
  • Technical
  • Relative Strength Index (RSI)
  • AACG 43.43
  • EQ 37.66
  • Support Level
  • AACG $1.18
  • EQ $0.90
  • Resistance Level
  • AACG $1.36
  • EQ $1.02
  • Average True Range (ATR)
  • AACG 0.11
  • EQ 0.14
  • MACD
  • AACG -0.00
  • EQ 0.00
  • Stochastic Oscillator
  • AACG 33.33
  • EQ 35.45

About AACG ATA Creativity Global

ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments of the company are (i) Overseas art study services (ii) Other educational services and (iii) Other services. Majority of its revenue comes from Overseas art study services.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: